Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 6/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2210452 | 0.80 | PDE7A (0.37) | KDRDHFRCYP1A2DYRK1AMAPK1 | |
| SCHEMBL4555081 | 0.76 | KDR (0.45) | KDRPDGFRATDP1METALDH1A1 | |
| SCHEMBL2209181 | 0.76 | KDR (0.41) | KDRPDGFRAMETCYP3A4LMNA | |
| SCHEMBL5050795 | 0.76 | PDGFRA (0.61) | KDRPDGFRAMET | |
| SCHEMBL2206780 | 0.76 | FGFR2 (0.43) | KDRPDGFRANOS3NOS1NOS2 | |
| SCHEMBL16432308 | 0.75 | NOS3 (0.46) | NOS3NOS1NOS2CYP1A2DYRK1A | |
| SCHEMBL2206890 | 0.75 | KDR (0.41) | KDRPDGFRAMETLMNAMEN1 | |
| SCHEMBL15663510 | 0.74 | KDR (0.40) | KDRPDGFRAMETCYP3A4LMNA | |
| SCHEMBL2209534 | 0.74 | MAPT (0.48) | KDRTDP1ALDH1A1LMNAMEN1 | |
| SCHEMBL15663783 | 0.74 | KDR (0.40) | KDRPDGFRAMETCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126935-B2 | Aurora kinase modulators and methods of use | AMGEN INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126935-B2 | Aurora kinase modulators and methods of use | AMGEN INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126935-B2 | Aurora kinase modulators and methods of use | AMGEN INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2010019473-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019473-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-2137177-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, CDK1 | KDR 644/4885PDGFRA 1102/4885DHFR 826/4885 |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | KDR 644/4885PDGFRA 1102/4885DHFR 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.